Anika Therapeutics Inc (ANIK):企業の財務・戦略的SWOT分析

◆英語タイトル:Anika Therapeutics Inc (ANIK) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C5266
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Anika Therapeutics Inc (ANIK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products include viscosupplementation and regenerative orthopedics products, advanced wound care devices, anti-adhesion gels, viscoelastic ophthalmic products, dental bone grafting adjuncts and joint dysfunction management fluids for horses. Its products are made from hyaluronic acid (HA) based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Anika has research and manufacturing facilities in Bedford, Massachusetts. The company offers its products through distributors in the Americas, Europe, the Middle East, and Asia. Anika is headquartered in Massachusetts, the US.

Anika Therapeutics Inc Key Recent Developments

Sep 05,2018: Anika appoints Dr. Cheryl Blanchard to its Board of Directors
Jul 25,2018: Anika reports second quarter 2018 financial results
May 02,2018: Anika Reports First Quarter 2018 Financial Results
Mar 05,2018: Anika Therapeutics Names Joseph Darling As CEO And Director
Feb 21,2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Anika Therapeutics Inc – Key Facts 6
Anika Therapeutics Inc – Key Employees 7
Anika Therapeutics Inc – Key Employee Biographies 8
Anika Therapeutics Inc – Major Products and Services 9
Anika Therapeutics Inc – History 11
Anika Therapeutics Inc – Company Statement 14
Anika Therapeutics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Anika Therapeutics Inc – Business Description 17
Business Segment: Dermal 17
Overview 17
Performance 17
Business Segment: Orthobiologics 17
Overview 17
Performance 17
Business Segment: Other 17
Overview 17
Business Segment: Others 18
Performance 18
Business Segment: Surgical 18
Overview 18
Performance 18
Geographical Segment: Europe 18
Target Markets 18
Performance 18
Geographical Segment: Other 18
Target Markets 18
Performance 18
Geographical Segment: US 19
Performance 19
R&D Overview 19
Anika Therapeutics Inc – Corporate Strategy 20
Anika Therapeutics Inc – SWOT Analysis 21
SWOT Analysis – Overview 21
Anika Therapeutics Inc – Strengths 21
Anika Therapeutics Inc – Weaknesses 22
Anika Therapeutics Inc – Opportunities 23
Anika Therapeutics Inc – Threats 24
Anika Therapeutics Inc – Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios – Capital Market Ratios 26
Financial Ratios – Annual Ratios 27
Performance Chart 30
Financial Performance 30
Financial Ratios – Interim Ratios 31
Financial Ratios – Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Anika Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 33
Anika Therapeutics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 34
Anika Therapeutics Inc, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Sep 05, 2018: Anika appoints Dr. Cheryl Blanchard to its Board of Directors 36
Jul 25, 2018: Anika reports second quarter 2018 financial results 37
May 02, 2018: Anika Reports First Quarter 2018 Financial Results 38
Mar 05, 2018: Anika Therapeutics Names Joseph Darling As CEO And Director 40
Feb 21, 2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results 41
Oct 25, 2017: Anika Reports Third Quarter 2017 Financial Results 42
Oct 23, 2017: Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer 43
Aug 28, 2017: Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs 44
Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 45
Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Anika Therapeutics Inc, Key Facts 6
Anika Therapeutics Inc, Key Employees 7
Anika Therapeutics Inc, Key Employee Biographies 8
Anika Therapeutics Inc, Major Products and Services 9
Anika Therapeutics Inc, History 11
Anika Therapeutics Inc, Subsidiaries 15
Anika Therapeutics Inc, Key Competitors 25
Anika Therapeutics Inc, Ratios based on current share price 26
Anika Therapeutics Inc, Annual Ratios 27
Anika Therapeutics Inc, Annual Ratios (Cont...1) 28
Anika Therapeutics Inc, Annual Ratios (Cont...2) 29
Anika Therapeutics Inc, Interim Ratios 31
Anika Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 33
Anika Therapeutics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 34
Anika Therapeutics Inc, Recent Deals Summary 35
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List of Figures
Anika Therapeutics Inc, Performance Chart (2013 - 2017) 30
Anika Therapeutics Inc, Ratio Charts 32
Anika Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 33
Anika Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 34

★海外企業調査レポート[Anika Therapeutics Inc (ANIK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Jelf Group PLC:企業のM&A・事業提携・投資動向
    Jelf Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jelf Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • SalvaRx Group plc (SALV):企業の財務・戦略的SWOT分析
    Summary SalvaRx Group Plc (SalvaRx), formerly 3Legs Resources plc, is a drug development company that offers acquiring and operating drug development programmes in immuno-oncology. The company offers immune oncology. It invests in novel cancer immune-therapies. SalvaRx provides development of a pipe …
  • General Electric Company:企業のM&A・事業提携・投資動向
    General Electric Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's General Electric Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Tandem Diabetes Care Inc (TNDM):企業の製品パイプライン分析
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device manufacturing company that designs and develops diabetic care products. The company's product portfolio includes t:slim X2 insulin pump, basal-IQ technology, software and applications, infusion sets and other pump accessories. It also pro …
  • Australian Postal Corporation:企業の戦略・SWOT・財務情報
    Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report Summary Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Helius Medical Technologies Inc (HSM):企業の製品パイプライン分析2018
    Summary Helius Medical Technologies Inc (HMT) is a medical device company that provides neurological wellness solutions. The company provides development, licensing and acquisition of non-invasive platform technologies for amplifying the brain’s ability to heal itself. It provides development of tec …
  • Avantis Medical Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Avantis Medical Systems Inc (AMS) is a medical device company that provides visualization technology solutions. The company uses its technology platform and software analysis for the screening and early detection of cancer. It offers products such as single camera colonoscopy devices and thi …
  • 4D Molecular Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary 4D Molecular Therapeutics Inc (4D Molecular Therapeutics) is a gene therapy company that deliver genes to specific cells in the body to eradicate rare and large market diseases. The company discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. It …
  • Veeco Instruments Inc (VECO):企業の財務・戦略的SWOT分析
    Summary Veeco Instruments Inc (Veeco) is a technology company that designs, manufacture and markets thin film and semiconductor equipment. The company offers various products and technologies which include MOCVD systems, precision surface processing system, MBE technologies, and ion beam sputtering. …
  • Parkson Retail Group Limited:戦略・SWOT・企業財務分析
    Parkson Retail Group Limited - Strategy, SWOT and Corporate Finance Report Summary Parkson Retail Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GlaxoSmithkline Consumer Healthcare Ltd:企業の戦略・SWOT・財務情報
    GlaxoSmithkline Consumer Healthcare Ltd - Strategy, SWOT and Corporate Finance Report Summary GlaxoSmithkline Consumer Healthcare Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Biogen Inc (BIIB):医療機器:M&Aディール及び事業提携情報
    Summary Biogen Inc (Biogen) is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fu …
  • Celator Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Celator Pharmaceuticals Inc (Celator) is a clinical-stage biopharmaceutical company that develops and distributes therapies for treating cancer disease. The company’s products include cytarabine and daunorubicin liposomal formulation, irinotecan HCI and floxuridine and hydrophobic docetaxel …
  • Banco Santander SA:戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company offers product candidate such as Xenleta (lefamulin), CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for th …
  • ReWalk Robotics Ltd (RWLK):企業の製品パイプライン分析
    Summary ReWalk Robotics Ltd (ReWalk) is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include ReWalk personal system and ReWalk rehabilita …
  • Viettel Group:企業の戦略・SWOT・財務分析
    Viettel Group - Strategy, SWOT and Corporate Finance Report Summary Viettel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mitralign Inc:医療機器:M&Aディール及び事業提携情報
    Summary Mitralign Inc (Mitralign) is a medical device company that offers direct transcatheter annuloplasty system to treat both functional tricuspid regurgitation and mitral regurgitation. The company’s products include crossing wire, pledget delivery catheter and placation lock delivery catheter, …
  • Wacker Neuson Se:企業の戦略・SWOT・財務分析
    Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report Summary Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Amryt Pharma Plc (AMYT):企業の財務・戦略的SWOT分析
    Amryt Pharma Plc (AMYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆